← Leaderboards
Stefan G Sarafianos
Emory University
$26,943,765
Attributed
$41,495,970
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$93,369,179 · 22
By mechanism
U54$58,508,719 · 7
R01$29,832,147 · 9
R37$3,006,648 · 1
R21$1,681,181 · 4
P50$340,484 · 1
Top collaborators
- Zhengqiang Wang30 shared
- Bruce Edward Torbett15 shared
- Atsuko Hachiya6 shared
- Dmitry Lyumkis6 shared
- Gregory B Melikian4 shared
- Michael A Parniak4 shared
- Donald H Burke2 shared
- Haian Fu2 shared
Most similar at Emory University
Same institution · by research overlap
- Rama Rao Amara$90,840,294
- Alexa Anne Snyder$192,958
- Haian Fu$16,783,892
- Raymond J Dingledine$29,610,268
- Sijia Tao$210,392
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusStructureResistanceBaseMolecularCellsDrug ResistanceDesignBiochemicalComplexHiv-1ViralMutationPharmaceutical PreparationsProteinsReverse TranscriptionVirologyInnovationResistance MutationBindingInsightAntiviral AgentsLeadAffect
Grant awards (100)
Behavior of HIV in Viral Environments (B-HIVE)$5,862,824
U54 · FY2025 · AI
Dynamics of HIV Core Interactions$1,041,134
U54 · FY2025 · AI · contact PI
Discovery of Antivirals Targeting Mpox Virus$767,057
R01 · FY2025 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$695,135
R01 · FY2025 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$626,362
R37 · FY2025 · AI · contact PI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$526,582
R01 · FY2025 · AI · contact PI
Behavior of HIV in Viral Environments (B-HIVE)$5,911,895
U54 · FY2024 · AI
Dynamics of HIV Core Interactions$1,090,645
U54 · FY2024 · AI · contact PI
Discovery of Antivirals Targeting Mpox Virus$782,142
R01 · FY2024 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$678,703
R01 · FY2024 · AI · contact PI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$530,513
R01 · FY2024 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$470,870
R37 · FY2024 · AI · contact PI
Dynamics of HIV Core Interactions$253,415
U54 · FY2024 · AI · contact PI
Experimental characterization and computational modeling of intrinsic bioreactivity of SuFEx/covalent nucleophile warheads$253,415
U54 · FY2024 · AI
Affinity Gradient-Based Transport of HIV Capsid Cores through the Nuclear Pore Complex$195,625
R21 · FY2024 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay$75,307
R01 · FY2024 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$13,952
R01 · FY2024 · AI · contact PI
Behavior of HIV in Viral Environments (B-HIVE)$6,759,300
U54 · FY2023 · AI
Dynamics of HIV Core Interactions$1,171,418
U54 · FY2023 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$643,490
R01 · FY2023 · AI · contact PI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$534,364
R01 · FY2023 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2023 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$470,524
R37 · FY2023 · AI · contact PI
Affinity Gradient-Based Transport of HIV Capsid Cores through the Nuclear Pore Complex$234,750
R21 · FY2023 · AI
Behavior of HIV in Viral Environments (B-HIVE)$6,289,044
U54 · FY2022 · AI
Molecular Interactions of HIV-1 with the Nuclear Pore Complex$1,348,805
R01 · FY2022 · AI
Dynamics of HIV Core Interactions$1,228,602
U54 · FY2022 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$657,615
R01 · FY2022 · AI · contact PI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$538,140
R01 · FY2022 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2022 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$470,199
R37 · FY2022 · AI · contact PI
HIV Interactions In Viral Evolution$5,340,254
U54 · FY2021 · AI
Molecular Interactions of HIV-1 with the Nuclear Pore Complex$1,369,167
R01 · FY2021 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$551,383
R01 · FY2021 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$512,250
R01 · FY2021 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$469,885
R37 · FY2021 · AI · contact PI
HIV-host interactions driving virus reverse transcription$274,426
U54 · FY2021 · AI · contact PI
HIV Interactions In Viral Evolution$5,014,695
U54 · FY2020 · AI
Molecular Interactions of HIV-1 with the Nuclear Pore Complex$1,381,064
R01 · FY2020 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$568,676
R01 · FY2020 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2020 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$498,808
R37 · FY2020 · AI · contact PI
HIV-host interactions driving virus reverse transcription$305,035
U54 · FY2020 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$57,898
R01 · FY2020 · AI · contact PI
HIV Interactions In Viral Evolution$5,317,846
U54 · FY2019 · AI
Molecular Interactions of HIV-1 with the Nuclear Pore Complex$1,435,582
R01 · FY2019 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$579,866
R01 · FY2019 · AI · contact PI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$522,974
R01 · FY2019 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$446,402
R01 · FY2019 · AI · contact PI
HIV-host interactions driving virus reverse transcription$426,281
U54 · FY2019 · AI · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$316,618
R01 · FY2019 · GM · contact PI
HIV Interactions In Viral Evolution$5,331,960
U54 · FY2018 · GM
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$590,494
R01 · FY2018 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$438,413
R01 · FY2018 · AI · contact PI
HIV-host interactions driving virus reverse transcription$409,972
U54 · FY2018 · GM · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$346,310
R01 · FY2018 · AI · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$318,086
R01 · FY2018 · GM · contact PI
HIV Interactions In Viral Evolution$260,833
U54 · FY2018 · GM
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$79,645
R01 · FY2018 · GM · contact PI
HIV Interactions In Viral Evolution$5,531,143
U54 · FY2017 · GM
HIV-host interactions driving virus reverse transcription$434,582
U54 · FY2017 · GM · contact PI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$425,333
R01 · FY2017 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$384,959
R01 · FY2017 · AI · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$281,785
R01 · FY2017 · GM · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$270,423
R01 · FY2017 · AI · contact PI
RNA Aptamers that Differentiate Among HIV-1 Capsid Assembly States$230,250
R21 · FY2017 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$220,564
R01 · FY2017 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$160,502
R01 · FY2017 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$117,365
R01 · FY2017 · AI · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$77,474
R01 · FY2017 · GM · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$749,422
R01 · FY2016 · AI · contact PI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$617,972
R01 · FY2016 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$511,509
R01 · FY2016 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$413,171
R01 · FY2016 · AI · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$373,673
R01 · FY2016 · GM · contact PI
RNA Aptamers that Differentiate Among HIV-1 Capsid Assembly States$191,875
R21 · FY2016 · AI
Project 12$176,740
P50 · FY2016 · GM · contact PI
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes$124,050
R01 · FY2016 · GM · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$13,841
R01 · FY2016 · AI · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$751,724
R01 · FY2015 · AI · contact PI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$465,907
R01 · FY2015 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$379,878
R01 · FY2015 · AI · contact PI
Capsid-Targeting Small Molecules Blocking HIV through Novel Mechanism of Action$226,102
R21 · FY2015 · AI · contact PI
Project 12$163,744
P50 · FY2015 · GM · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$24,291
R01 · FY2015 · AI · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$748,607
R01 · FY2014 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$392,694
R01 · FY2014 · AI · contact PI
Capsid-Targeting Small Molecules Blocking HIV through Novel Mechanism of Action$187,848
R21 · FY2014 · AI · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$4,564
R01 · FY2014 · AI · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$643,710
R01 · FY2013 · AI · contact PI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$710,548
R01 · FY2012 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$360,279
R01 · FY2012 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$360,455
R01 · FY2011 · AI · contact PI
Structure-based expansion of neutralization ability of KD-247, an anti-V3 mAb$187,481
R21 · FY2011 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$364,269
R01 · FY2010 · AI · contact PI
Structure-based expansion of neutralization ability of KD-247, an anti-V3 mAb$227,250
R21 · FY2010 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$368,116
R01 · FY2009 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$256,512
R01 · FY2009 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$50,304
R01 · FY2009 · AI · contact PI
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV$380,655
R01 · FY2008 · AI · contact PI